REENGINEERING DRUG DEVELOPMENT - INTEGRATING PHARMACOECONOMIC RESEARCH INTO THE DRUG DEVELOPMENT PROCESS

被引:0
|
作者
DATA, JL
WILLKE, RJ
BARNES, JR
DIROMA, PJ
机构
关键词
PHARMACOECONOMICS; DRUG DEVELOPMENT; REENGINEERING; REGULATORY ISSUES;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacoeconomic research will be an increasingly important aspect of drug development as providers, third-party payers, and worldwide government health agencies use cost-effectiveness and quality-of-life data to assist in making decisions on optimal pharmaceutical treatment protocols, formulary listings, and reimbursement. It is in the best interest of pharmaceutical companies to have an established, well-integrated pharmacoeconomic research program that can respond to the dynamic health-care environment and proactively plan a program to optimize patient care. The new paradigm for pharmacoeconomic research will require establishment and successful management of many internal and external customer relationships. This article discusses one company's organization of these relationships and how they are integrated into the drug development process during each stage of the product life cycle.(2)
引用
收藏
页码:67 / 73
页数:7
相关论文
共 50 条
  • [41] Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information
    Ishiguro, Akihiro
    Sato, Reiko
    Nagai, Naomi
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : 12 - 17
  • [42] Drug discovery and development: lessons from an undeveloped drug
    Gordi, Toufigh
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (02) : 157 - 162
  • [43] Understanding Drug Development: A Primer on the Food and Drug Administration
    Purandare, Amol, V
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (10) : 977 - 981
  • [44] Systems pharmacology to predict drug safety in drug development
    Trame, Mirjam N.
    Biliouris, Konstantinos
    Lesko, Lawrence J.
    Mettetal, Jerome T.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 94 : 93 - 95
  • [45] Atherosclerosis imaging in drug development
    Nicholls, Stephen J.
    Kalidindi, Srinivasa
    Moon, Keon-Woong
    Nissen, Steven E.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (09) : 1241 - 1250
  • [46] Obesity and Pediatric Drug Development
    Vaughns, Janelle D.
    Conklin, Laurie S.
    Long, Ying
    Zheng, Panli
    Faruque, Fahim
    Green, Dionna J.
    van den Anker, John N.
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05) : 650 - 661
  • [47] Drug development in paediatric oncology
    Benninger-Doering, G.
    Boos, J.
    KLINISCHE PADIATRIE, 2006, 218 (03): : 152 - 156
  • [48] Drug development for cystic fibrosis
    Sanders, Don B.
    Chmiel, James F.
    PEDIATRIC PULMONOLOGY, 2021, 56 : S10 - S22
  • [49] Implications of Pharmacogenomics for Drug Development
    Kirk, Randal J.
    Hung, Jeffrey L.
    Horner, Scorr R.
    Perez, Jeffrey T.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (12) : 1484 - 1497
  • [50] Drug development and licensing in diabetes
    Llano, Andrea
    Fisher, Miles
    Mckay, Gerry
    PRACTICAL DIABETES, 2016, 33 (02) : 60 - 64